A Phase IIa, Open-Label, Randomized Trial in Treatment-naive HIV-1-Infected Subjects to Determine the Antiviral Activity of 14 Days of Monotherapy With 2 Different b.i.d. Dose Regimens of TMC310911 Coadministered With Ritonavir.

Trial Profile

A Phase IIa, Open-Label, Randomized Trial in Treatment-naive HIV-1-Infected Subjects to Determine the Antiviral Activity of 14 Days of Monotherapy With 2 Different b.i.d. Dose Regimens of TMC310911 Coadministered With Ritonavir.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs TMC 310911 (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Oct 2013 Results published in JAIDS.
    • 30 Apr 2013 TMC310911 had a favorable safety and tolerability profile and demonstrated clinical proof-of-concept, according to a, Ascletis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top